[Skip to Content]

Upstate Active Clinical Trials

Study Title:

AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in
Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

What is the purpose of the study? (in Layman's terms, please describe the study)

The overall goal of this study is to find out what effect, good and/or bad, the drug inotuzumab ozogamicin has on children and young adults with relapsed or refractory
B-ALL.

Upstate Institutional Review Board (IRB) Number:

1083652

Study/Protocol ID:

AALL1621

Study Phase:

Phase III

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who is eligible?

> or = 1 year and < 22 years of age at time of enrollment

What is involved if I participate?

  • How long is the study?
    about 3 months
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    standard of care

Where will the study take place?

cancer center

Other Information:

none

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top